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Tau pathology is characteristic of Alzheimer’s disease
(AD) and related tauopathies including Parkinson’s disease
(PD) wherein a significant percentage of PD patients
who develop dementia harbor AD-like tau pathology. Tau
pathology is characterized by insoluble filamentous aggre-
gates of hyperphosphorylated tau in CNS neurons known as
neurofibrillary tangles (NFTs) and neuropil threads (NTs).
NFTs and NTs are implicated in mechanisms of neuro-
degeneration through gains of toxic functions or losses of
normal tau functions. Hyperphosphorylation and dec-
reased solubility of tau leads to a loss of the ability of tau
to bind to and stabilize microtubules (MTs) which impairs
axonal transport and results in neuronal dysfunction and
degeneration. This presentation describes the use of MT
stabilizing drugs to counteract the loss of tau function
and prevent/ameliorate tau mediated neurodegeneration
in a transgenic (Tg) mouse model of an AD-like neuro-
degenerative tauopathy. Briefly, proof of concept preven-
tion and intervention studies of the brain-penetrant
MT-stabilizing agent epothilone D (EpoD) are described
in young (prevention) and aged (intervention) P301S
mutant tau Tg mice (PS 19 mice) with little (young PS 19
mice) or abundant tau pathology and behavioral impair-
ments (aged PS19 mice). In the prevention and interven-
tion studies, EpoD treatment reduced axonal dystrophy
and increased axonal MT density which led to improved
neuronal integrity and cognitive performance. EpoD treat-
ment also improved fast axonal transport in the aged PS19
Tg mice. Unexpectedly, aged PS19 mice treated with
EpoD showed a marked reduction in forebrain tau pathol-
ogy and increased hippocampal neuronal integrity. There
were no dose-limiting side effects in the EpoD treated
young and aged PS19 mice. These studies support the
view that EpoD and other brain-penetrant MT-stabilizing
drugs offset the loss of tau function in neurodegenerative
tauopathies and therefore are potential therapeutics for
the treatment of AD and related tauopathies. Finally, a
new seeded transmission model of tauopathy is presented
using injections of preformed tau fibrils into the brains of
PS19 mice which presents new opportunities to assess the
efficacy of MT stabilizers and other potential passive
immunization therapies for AD and related tauopathies.
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